Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$16.43M$16.43Mderived+122.6% vs Q4 2019 Net Income$1.36M$1.36MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$8,604,021+92.4% Operating Incomederived$1,356,468N/M Operating Cash Flowderived-$2,592,605N/M Free Cash Flowderived-$2,615,392N/M Margins · derivedGross margin52.4%−8.2 pt vs Q4 2019
Operating margin8.3%+39.7 pt vs Q4 2019
Net margin8.3%+35.2 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 8, 2021 · 67 d after period end